Non-erosive Reflux Disease | The Changes of Ryodoraku and HRV After PPI Treatment in GERD Patients
Non-erosive Reflux Disease research study
What is the primary objective of this study?
Gastroesophageal reflux disease(GERD) mainly related to the reflux of stomach content induced by the dysfunction of lower esophageal sphincter. Proton pump inhibitors (PPI) can effectively block gastric acid secretion but the drug reactions and the degree of improvement in symptoms are sometimes unpredictable. The aim of this study is to investigate the association between the clinical efficacy of PPI in patients with GERD and the personal physical status by Ryodoraku and ANSWatch.
Who is eligible to participate?
Inclusion Criteria: - male or female - age of 20-75 years - patients with GERD who have to receive PPIs for four weeks Exclusion Criteria: - Suffering from peptic ulcer, gallstones, cancer, and Barrett's esophagus - previously underwent the esophagus, stomach or duodenum surgery - Lactating women or pregnant women
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Non-erosive Reflux Disease
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Device:RyodorakuRyodoraku to assess the energy of meridian system for each patient before and after taking the medication
Device:ANSWatchANSWatch to assess the autonomic nervous system for each patient before and after taking the medication
Device:UGI endoscopyUGI endoscopy to assess the grade of reflux esophagitis for each patient before and after taking the medication
Other:GerdQGerdQ to assess the severity of GERD for each patient before and after taking the medication
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
PPI treatmentPatients with GERD would be assessed by ANSWatch. Ryodoraku, UGI endoscopy, and GerdQ before taking PPIs and after taking PPI 20mg tablet by mouth everyday for 4 weeks.
Start Date: May 2014
Completed Date: July 2016
Primary Outcome: gastroesophageal reflux disease questionnaire
Secondary Outcome: Upper gastrointestinal endoscopy
Study sponsors, principal investigator, and references
Principal Investigator: Mei-Ling Shen, M.D
Lead Sponsor: Taichung Tzu Chi Hospital